HC Wainwright Issues Positive Estimate for DAWN Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – HC Wainwright lifted their Q1 2025 earnings per share estimates for Day One Biopharmaceuticals in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.28) for the quarter, up from their prior estimate of ($0.34). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ Q2 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.94) EPS, FY2026 earnings at $0.34 EPS, FY2027 earnings at $0.58 EPS, FY2028 earnings at $1.21 EPS and FY2029 earnings at $1.73 EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The company had revenue of $29.21 million during the quarter, compared to analyst estimates of $27.11 million.

Other research analysts have also recently issued reports about the company. The Goldman Sachs Group reduced their price target on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, February 10th. Needham & Company LLC restated a “buy” rating and issued a $32.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday. TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. Wedbush restated an “outperform” rating and issued a $32.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday. Finally, Bank of America reduced their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $34.86.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ DAWN opened at $9.44 on Friday. The stock has a 50 day moving average price of $12.23 and a 200 day moving average price of $13.41. Day One Biopharmaceuticals has a 52 week low of $9.43 and a 52 week high of $18.07. The stock has a market capitalization of $951.99 million, a PE ratio of -9.17 and a beta of -1.46.

Insider Buying and Selling

In related news, CFO Charles N. York II sold 4,370 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $52,265.20. Following the sale, the chief financial officer now directly owns 252,638 shares in the company, valued at $3,021,550.48. This trade represents a 1.70 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeremy Bender sold 12,048 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $144,094.08. Following the sale, the chief executive officer now directly owns 128,015 shares of the company’s stock, valued at approximately $1,531,059.40. This trade represents a 8.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,064 shares of company stock worth $651,225 in the last ninety days. Company insiders own 8.40% of the company’s stock.

Institutional Trading of Day One Biopharmaceuticals

Large investors have recently modified their holdings of the stock. FMR LLC raised its holdings in shares of Day One Biopharmaceuticals by 73.9% in the 4th quarter. FMR LLC now owns 12,887,467 shares of the company’s stock worth $163,284,000 after purchasing an additional 5,475,087 shares during the period. Alyeska Investment Group L.P. purchased a new position in Day One Biopharmaceuticals during the fourth quarter valued at $31,829,000. Braidwell LP raised its stake in Day One Biopharmaceuticals by 60.5% during the third quarter. Braidwell LP now owns 4,873,853 shares of the company’s stock valued at $67,893,000 after buying an additional 1,837,949 shares during the last quarter. Vestal Point Capital LP raised its stake in Day One Biopharmaceuticals by 100.0% during the third quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock valued at $34,825,000 after buying an additional 1,250,000 shares during the last quarter. Finally, Boxer Capital Management LLC purchased a new position in Day One Biopharmaceuticals during the fourth quarter valued at $15,077,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.